These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15573801)

  • 1. Lessons learned after the withdrawal of rofecoxib.
    Giaquinta D
    Manag Care Interface; 2004 Nov; 17(11):25-6, 46. PubMed ID: 15573801
    [No Abstract]   [Full Text] [Related]  

  • 2. Failing the public health--rofecoxib, Merck, and the FDA.
    Topol EJ
    N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193
    [No Abstract]   [Full Text] [Related]  

  • 3. COX-2 inhibitor use after Vioxx: careful balance or end of the rope?
    Fendrick AM
    Am J Manag Care; 2004 Nov; 10(11 Pt 1):740-1. PubMed ID: 15623263
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 5. Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib).
    Carné X; Cruz N
    Eur J Epidemiol; 2005; 20(2):127-9. PubMed ID: 15792277
    [No Abstract]   [Full Text] [Related]  

  • 6. Learning the value of drugs--is rofecoxib a regulatory success story?
    Eisenberg RS
    N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
    [No Abstract]   [Full Text] [Related]  

  • 7. Experts point to lessons learned from controversy over rofecoxib safety.
    Hampton T
    JAMA; 2005 Jan; 293(4):413-4. PubMed ID: 15671414
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors.
    Couzin J
    Science; 2004 Oct; 306(5695):384-5. PubMed ID: 15486258
    [No Abstract]   [Full Text] [Related]  

  • 9. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 10. How to avoid another 'Vioxx'.
    Frantz S
    Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA warns Merck over its promotion of rofecoxib.
    Josefson D
    BMJ; 2001 Oct; 323(7316):767. PubMed ID: 11588068
    [No Abstract]   [Full Text] [Related]  

  • 12. Rofecoxib, Merck, and the FDA.
    Kim PS; Reicin AS
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342
    [No Abstract]   [Full Text] [Related]  

  • 13. Merck VIOXX "warning" is questioned.
    Allen TS; Henderson JH
    Tex Med; 2005 May; 101(5):5-6. PubMed ID: 15948521
    [No Abstract]   [Full Text] [Related]  

  • 14. COX-2 selective inhibitors--important lessons learned.
    Maxwell SR; Webb DJ
    Lancet; 2005 Feb 5-11; 365(9458):449-51. PubMed ID: 15705439
    [No Abstract]   [Full Text] [Related]  

  • 15. [Funtional phase IV?].
    Heinzl S
    Med Monatsschr Pharm; 2005 Jan; 28(1):1. PubMed ID: 15693597
    [No Abstract]   [Full Text] [Related]  

  • 16. Rofecoxib, Merck, and the FDA.
    Villalba L; Witter J
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke.
    Lenzer J
    BMJ; 2005 Feb; 330(7489):440. PubMed ID: 15731142
    [No Abstract]   [Full Text] [Related]  

  • 18. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational studies and the withdrawal of rofecoxib.
    Watson DJ; Santanello NC
    Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):199-201; author reply 203-5. PubMed ID: 16508998
    [No Abstract]   [Full Text] [Related]  

  • 20. Rofecoxib, Merck, and the FDA.
    Wolfe MM
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.